Is Novo Nordisk Stock a Buy?

Few companies garner as much reliable attention as Novo Nordisk (NYSE: NVO) does these days. With a bull market coinciding with a historic run of growth for the Danish pharmaceutical giant related to its GLP-1 drugs, it's no surprise that its share prices have nearly doubled over the last three years.But with such strong performance lately, can the stock be as good a purchase for investors going forward? To find out, let's take a look at what it has planned.Novo Nordisk is among the fastest-growing big pharma competitors, which makes it easy to formulate a long list of reasons to buy its stock. In the third quarter, normalized diluted earnings per share (EPS) rose by 27.2% compared to the same quarter a year prior, reaching $0.90; trailing-12-month (TTM) revenue of $39.3 billion is also up by 16.7% year over year.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool